Krystal Biotech, Inc. (KRYS) stock
Close on Nov 12, 2026Market cap $9.05BP/E 41.5Yield –
Krystal Biotech, Inc. grew revenue 26.0% to $470.03M over the twelve months to Sep 30, 2026. Operating income rose 43.6% to $227.52M, moving the operating margin from 42.4% to 48.4%. Free cash flow was $310.08M, up 87.3% from a year earlier. At the latest close the market valued the company at $9.05B, 41.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $9.05B
- P/E ratio
- 41.5
- Price to sales
- 19.25
- Price to book
- 6.30
- Dividend yield
- –
- Free cash flow yield
- 3.43%
Fundamentals
- Revenue
- $470.03M
- Net income
- $225.17M
- EPS, diluted
- $7.37
- Free cash flow
- $310.08M
- Book value per share
- $46.55
- Diluted shares
- 31M
Trading
- Next earnings
- Jan 11, 2027 (estimated, before the open)
- Previous close
- $308.81
- Open
- $307.72
- Day's range
- $304.06 – $309.68
- Volume
- 157,099
- Average volume (20 days)
- 321,867
- Index membership
- S&P SmallCap 600 (since Aug 2024), Russell 2000, Russell 3000
- Beta (5 years)
- 0.84
- 52-week range
- $198.02 – $382.54
- RSI (14 days)
- 45.0
- Volatility (1 year)
- 39.3%
- Relative volume
- 0.48×
- WACC
- 9.1%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KRYS | S&P 500 | Difference | KRYS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -7.9% | -2.7% | −5.3 pts | ||
| 3 months | -8.2% | -1.7% | −6.4 pts | ||
| Year to date | +24.0% | +11.9% | +12.1 pts | ||
| 1 year | +50.6% | +12.0% | +38.6 pts | ||
| 3 years | +210.1% | +78.2% | +132.0 pts | +45.8% | +21.2% |
| 5 years | +543.5% | +73.2% | +470.3 pts | +45.1% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Krystal Biotech filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- Results
About Krystal Biotech
Biological Products, (No Diagnostic Substances)
The company discovers, manufactures, and commercializes redosable genetic medicines designed to treat rare and debilitating conditions with substantial unmet medical needs. Utilizing a proprietary gene therapy platform engineered from herpes simplex virus-1, it produces targeted therapies that can be administered non-invasively at healthcare facilities or in home environments. Its principal commercial offering is Vyjuvek, an approved topical treatment for wounds caused by dystrophic epidermolysis bullosa. In addition to developing pipeline candidates for respiratory, dermatological, and ophthalmic diseases, the business addresses aesthetic conditions through its dedicated subsidiary, primarily serving pediatric and adult patients affected by serious genetic disorders.
Company profile, executives and historyKrystal Biotech stock: common questions
What is Krystal Biotech's stock price?
KRYS closed at $305.68 on Nov 12, 2026, down 1.01% on the day. Over the past 52 weeks it traded between $198.02 and $382.54.
What is Krystal Biotech's market cap?
Krystal Biotech was worth $9.05B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KRYS's P/E ratio?
KRYS trades at 41.5 times earnings, based on diluted earnings per share of $7.37 over the twelve months to Sep 30, 2026.
How much revenue does Krystal Biotech make?
Krystal Biotech reported revenue of $470.03M for the twelve months to Sep 30, 2026, up 26.0% from a year earlier.
Does Krystal Biotech pay a dividend?
No. Krystal Biotech has not paid a cash dividend over the last twelve months.
When does Krystal Biotech report earnings next?
Krystal Biotech is expected to report Q4 FY2026 results on Jan 11, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has KRYS stock performed over the past year?
Including dividends, KRYS returned +50.6% over the past year, against +12.0% for the S&P 500.
How many KRYS shares are sold short?
3M shares were sold short at the latest FINRA report, 12.43% of the float, or 12.2 days of average trading volume.
Who are Krystal Biotech's competitors?
Companies most similar to Krystal Biotech by business, industry and size include MGTX, BCRX, IMCR, ALVO, IOVA.
See a number that looks wrong?